Generated: December 17, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 019404
« Back to Dashboard
, which is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. Additional details are available on the OCUFEN profile page.
The generic ingredient in OCUFEN is flurbiprofen sodium. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the flurbiprofen sodium profile page.
Pharmacology for NDA: 019404
Suppliers and Packaging for NDA: 019404
||National Drug Code
||1 BOTTLE, DROPPER in 1 CARTON (11980-801-03) > 2.5 mL in 1 BOTTLE, DROPPER
||NDA AUTHORIZED GENERIC
||Rebel Distributors Corp
||1 BOTTLE, DROPPER in 1 CARTON (42254-023-25) > 2.5 mL in 1 BOTTLE, DROPPER
|Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Dec 31, 1986||TE:||AT||RLD:||Yes|
Expired Orange Book Patents for NDA: 019404
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.